Shots:

• The BTD is based on P-IIa assessing vixarelimab in reducing pruritus in patients with prurigo nodularis
• The study met its 1EPs i.e reduction in WI-NRS from baseline @8wks. in vixarelimab recipients and patients also received PN-IGA score of 0/1 @8wks.
• Kiniksa expects to initiate a P-IIb clinical trial of vixarelimab in prurigo nodularis- evaluating a range of once-monthly dose regimens- by the end of 2021. Vixarelimab is a fully-human mAb that targets oncostatin M receptor beta (OSMRβ)

 ­ Ref: GlobeNewswire | Image: Kiniksa